Health-related quality of life with belzutifan versus everolimus for advanced kidney cancer
People with kidney cancer have been shown to have changes (mutations) in [...]
Combinations of pembrolizumab and targeted therapies for advanced clear cell kidney cancer
The KEYMAKER-U03 study is looking at different combinations of immunotherapy [...]
Belzutifan approved in Europe for advanced kidney cancer and VHL disease
The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for [...]
Belzutifan plus cabozantinib combination shows promise in advanced kidney cancer
Updated results from the phase 2 LITESPARK-003 trial with belzutifan [...]
Belzutifan available on the NHS for patients with VHL disease
We are delighted to announce that the National Institute for [...]
Belzutifan compared to everolimus for advanced kidney cancer
People with kidney cancer have been shown to have changes (mutations) in [...]
Belzutifan and shows better quality of life compared to everolimus
People with kidney cancer have been shown to have changes [...]
FDA approves belzutifan for advanced kidney cancer
The Food and Drug Administration (FDA) in the United States [...]
Belzutifan for advanced kidney cancer: long-term follow-up
Studies looking at the genes of people with kidney cancer have shown [...]
ESMO 2023: Belzutifan for the treatment of advanced kidney cancer
Treatments for people with metastatic kidney cancer have changed over [...]
